Santé invests at the leading edge of innovation in Healthcare and Technology. We manage over a half-billion dollars of capital invested in two separate strategies.
Santé Ventures invests in innovative, early-stage healthcare companies across the Biotech, Medtech, and Healthtech industries.
Santé Capital leverages state-of-the-art machine learning in combination with proven investment expertise to produce attractive risk-adjusted returns in a systematic public equity strategy.
Santé Ventures invests in innovative, early-stage healthcare companies across the Biotech, Medtech, and Healthtech industries.
Santé Capital leverages state-of-the-art machine learning in combination with proven investment expertise to produce attractive risk-adjusted returns in a systematic public equity strategy.
Location: United States, Texas, Austin
Employees: 11-50
Founded date: 2006
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Mentions in press and media 19
| Date | Title | Description |
| 13.08.2025 | Reprieve Cardiovascular Secures $61 Million Financing and Enrolls First Patient in Pivotal Study | — Series B fundraise led by Deerfield Management enables scaling of pivotal clinical trial and commercial readiness activities for Reprieve® System – First patient enrolled in FASTR II study by Washington University School of Medicine in St... |
| 06.07.2024 | Endogenex: $88 Million Raised To Improve Outcomes In Individuals With Type 2 Diabetes | Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes, announced it closed an oversubscribed Series C financing totaling $88 million. The new funding round will be used to com... |
| 23.02.2024 | Reprieve Cardiovascular Revolutionizes Heart Failure Treatment with $42M Funding | Reprieve Cardiovascular, a Milford, MA-based company, secures $42M in Series A funding to advance intelligent fluid management for heart failure patients. Led by Lightstone Ventures and Sante Ventures, the funding will propel Reprieve's mis... |
| 22.02.2024 | Reprieve Cardiovascular Nabs $42M to Expand Intelligent Fluid Management for Heart Failure | What You Should Know: – Reprieve Cardiovascular, a pioneer in personalized fluid management for acute decompensated heart failure (ADHF) emerges from stealth launching with $42M in Series A financing round. – The Series A round was co-led b... |
| 28.10.2022 | 5 ways biotech startups can mitigate risk to grow sustainably in the long run | Omar Khalil Contributor Share on Twitter Omar Khalil is a partner at Santé Ventures, where he focuses primarily on biotechnology and medical technology companies. The unprecedented explosion of investment in life sciences over the past deca... |
| 18.09.2021 | Sante Ventures Raises $260 Million for its Fourth Fund | Sante Ventures, an early-stage healthcare, and life sciences investment firm, announced it has raised $260 million for its Fund IV. |
| 17.09.2021 | Santé Ventures closes Fund IV on $260M | Santé Ventures, a healthcare and life sciences investor, has closed its fourth namesake fund on $260 million. The Austin-based VC firm, which typically leads seed-stage and Series A rounds, will use the capital to invest in 15 to 25 startup... |
| 16.09.2021 | Santé Ventures Raises $260M Fourth Fund | Santé Ventures, an Austin, Texas- and Boston, MA-based early-stage healthcare and life sciences investment firm, closed its Fund IV, at $260m. Fund IV secured capital commitments from more than two-dozen limited partners, including the Penn... |
| 16.09.2021 | Santé Ventures Raises $260 Million in Fourth Fund | |
| 23.06.2021 | RapidPulse Launches with $15M for Ischemic Stroke Therapy | – RapidPulse, Inc., a Miami-based medical device company developing a novel aspiration system to treat ischemic stroke, today announced it has raised $15M in Series A funding led by Santé Ventures who was joined by Epidarex Capital, Hattera... |
Show more